TRACON Pharmaceuticals, Inc. (TCON)
- Previous Close
1.8900 - Open
1.8300 - Bid 1.7200 x 100
- Ask 1.8400 x 100
- Day's Range
1.7642 - 1.9687 - 52 Week Range
1.5900 - 16.8000 - Volume
128,510 - Avg. Volume
235,142 - Market Cap (intraday)
4.073M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2000 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.50
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
www.traconpharma.comRecent News: TCON
Performance Overview: TCON
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCON
Valuation Measures
Market Cap
4.07M
Enterprise Value
-4.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.35
Enterprise Value/EBITDA
-1.13
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.79%
Return on Assets (ttm)
-29.16%
Return on Equity (ttm)
--
Revenue (ttm)
12.04M
Net Income Avi to Common (ttm)
-3.59M
Diluted EPS (ttm)
-2.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.72M